The effect of 6-year osteoporosis treatment withzoledronic 5 mg (aclasta) in comparison with 3-yeartreatment: results from the horizon-pft.
Main Authors: | D Black, I. R. Reid, J. A. Cauley, S Boonen, F Cosman, P C Leung, P Lakatos, Z Man, S. R. Cummings, T. F. Hue, M. E. Ruzycky, R Martinez, G Su, C Bucci-Rechtweg, R Eastell |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2011-04-01
|
Series: | Остеопороз и остеопатии |
Online Access: | https://endojournals.ru/index.php/osteo/article/view/4132 |
Similar Items
-
EFFECT OF 6-YEAR TREATMENT OF OSTEOPOROSIS WITH ZOLEDRONIC ACID 5MG (ACLASTA) COMPARED WITH THE 3-YEAR-TREATMENT, RESULTS OF EXTENDED HORIZON PFT STUDY
by: D M Black, et al.
Published: (2012-04-01) -
PRIMENENIE ZOLEDRONOVOY KISLOTY 5 MG (PREPARAT «AKLASTA») ODIN RAZ V GOD dlya lecheniyazhenshchin s postmenopauzal'nym osteoporozom (issledovanie horizon-pft)
by: M. BLACK DENNIS, et al.
Published: (2008-04-01) -
Technology and Electrophysical Properties of Multiferroic PZT–PFT Ceramics
by: Niemiec P., et al.
Published: (2013-12-01) -
Thermal Variations in Osteoporosis After Aclasta® Administration: Case Study
by: Wally auf der Strasse, et al.
Published: (2020-09-01) -
Aclasta is a new standard of the efficiency of antiresorptive therapy: One-ayear infusion
by: A M Mkrtumyan, et al.
Published: (2008-03-01)